专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011151841A1 FERMENTATION PROCESS FOR STREPTOCOCCUS PNEUMONIAE 审中-公开
标题翻译：发病过程中发生肺结核
公开(公告)号：WO2011151841A1
公开(公告)日：2011-12-08
申请号：PCT/IN2011/000365
申请日：2011-05-26
申请人： PANACEA BIOTEC LIMITED , JAIN, Rajesh , MAITHAL, Kapil
发明人： JAIN, Rajesh , MAITHAL, Kapil
IPC分类号： C12N1/20 , C12R1/46
CPC分类号： C12N1/20 , C12R1/46
摘要： The invention relates to improvement of culture and fermentation conditions for propagation and production of biomass and capsular polysaccharides by Streptococcus pneumoniae . The invention in particular relates to a novel culture medium free of serum and animal component for production of biomass and polysaccharide. The novel and optimized growth medium, optimized growth parameters employed during the cultivation and the propagation of the bacteria, along with the other factors, result in a better biomass production as well as better saccharide yields by S. pneumoniae during fermentation.
摘要翻译：本发明涉及由肺炎链球菌传播和生产生物质和荚膜多糖的培养和发酵条件的改进。本发明特别涉及一种不含用于生产生物质和多糖的血清和动物组分的新型培养基。新颖优化的生长培养基，培养和细菌繁殖期间使用的优化生长参数以及其他因素，导致发酵期间肺炎链球菌生物质产量更好，更好的糖产量。

2. 发明申请

WO2010137036A3 JAPANESE ENCEPHALITIS VACCINE AND METHOD OF MANUFACTURING THE SAME 审中-公开
标题翻译：日本ENCEPHALITIS疫苗及其制造方法
公开(公告)号：WO2010137036A3
公开(公告)日：2011-05-26
申请号：PCT/IN2010000343
申请日：2010-05-21
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , GALGALKAR MILIND V , MAITHAL KAPIL , VRATI SUDHANSHU
发明人： JAIN RAJESH , GALGALKAR MILIND V , MAITHAL KAPIL , VRATI SUDHANSHU
IPC分类号： A61K39/12 , C12N5/00 , C12N7/06
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5252 , A61K2039/55505 , C12N2770/24134 , C12N2770/24151 , C12N2770/24163
摘要： The present invention relates to a novel Japanese encephalitis vaccine and a novel process for making the same. The invention in particular relates to a Japanese encephalitis virus strain P20778 vaccine, wherein the viral adaptation and propagation is carried out in a medium which is free of serum and additives of animal origin. The virus may be propagated particularly in Vero cell line.
摘要翻译：本发明涉及一种新型的日本脑炎疫苗及其制造方法。本发明特别涉及日本脑炎病毒株P20778疫苗，其中病毒适应和繁殖在不含血清和动物来源的添加剂的培养基中进行。病毒可能在Vero细胞系中特别传播。

3. 发明申请

WO2007043064A1 A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR CANCER 审中-公开
标题翻译：癌症的诊断标记和治疗目标
公开(公告)号：WO2007043064A1
公开(公告)日：2007-04-19
申请号：PCT/IN2006/000402
申请日：2006-10-06
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , CHANDRA, Harish , MUKHERJEE, Rama , BURMAN, Anand, C.
发明人： MAITHAL, Kapil , CHANDRA, Harish , MUKHERJEE, Rama , BURMAN, Anand, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/16
摘要： The present invention, in general, relates to use of nm23H1-B gene for diagnosing cancer susceptibility and metastatic progression in colon/colorectal cancer. In particular, the present invention relates to identifying the alteration in the expression of nm23H1-B gene on treatment with chemotherapeutic agents for diagnosing cancer susceptibility and metastatic progression in colon/colorectal cancer.
摘要翻译：本发明一般涉及nm23H1-B基因用于诊断结肠/结肠直肠癌中的癌症易感性和转移进展。特别地，本发明涉及鉴定nm23H1-B基因在用化学治疗剂治疗结肠/结肠直肠癌中的癌症易感性和转移进展的诊断方面的改变。

4. 发明申请

WO2010137036A2 NOVEL JAPANESE ENCEPHALITIS VACCINE AND METHOD OF MANUFACTURING THE SAME 审中-公开
标题翻译：新日本精神病毒疫苗及其制造方法
公开(公告)号：WO2010137036A2
公开(公告)日：2010-12-02
申请号：PCT/IN2010/000343
申请日：2010-05-21
申请人： PANACEA BIOTEC LTD , JAIN, Rajesh , GALGALKAR, Milind V , MAITHAL, Kapil , VRATI, Sudhanshu
发明人： JAIN, Rajesh , GALGALKAR, Milind V , MAITHAL, Kapil , VRATI, Sudhanshu
IPC分类号： A61K39/12
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5252 , A61K2039/55505 , C12N2770/24134 , C12N2770/24151 , C12N2770/24163 , Y02A50/39
摘要： The present invention relates to a novel Japanese encephalitis vaccine and a novel process for making the same. The invention in particular relates to a Japanese encephalitis virus strain P20778 vaccine, wherein the viral adaptation and propagation is carried out in a medium which is free of serum and additives of animal origin. The virus may be propagated particularly in Vero cell line.
摘要翻译：本发明涉及一种新型的日本脑炎疫苗及其制造方法。本发明特别涉及日本脑炎病毒株P20778疫苗，其中病毒适应和繁殖在不含血清和动物来源的添加剂的培养基中进行。病毒可能在Vero细胞系中特别传播。

5. 发明申请

WO2007072504A1 DNA VACCINE FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的DNA疫苗
公开(公告)号：WO2007072504A1
公开(公告)日：2007-06-28
申请号：PCT/IN2006/000497
申请日：2006-12-19
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , SENGUPTA, Paromita , MUKHERJEE, Rama
发明人： MAITHAL, Kapil , SENGUPTA, Paromita , MUKHERJEE, Rama
IPC分类号： A61K39/00 , C12N15/62 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/55516 , A61K2039/57 , A61K2039/6031 , C07K14/57563 , C07K14/705 , C07K14/71 , C07K2319/01 , C12N9/93
摘要： The invention relates to a fusion gene useful as a therapeutic and prophylactic vaccine against cancer. The fusion gene contains a DNA encoding ubiquitin gene fused to a second DNA encoding growth factor receptors or fragment thereof, over expressed in various types of cancer. In particular, the invention is illustrated by a recombinant fusion gene comprised of mutated ubiquitin gene and modified extra cellular domain of vasoactive intestinal peptide/ pituitary adenylate cyclase activating polypeptide receptor-1 (VPACl). Immunization with the vaccine will break the self- tolerance for the tumor antigen through effective antigen processing and presentation, leading to retardation/ regression of tumor growth.
摘要翻译：本发明涉及可用作抗癌治疗和预防性疫苗的融合基因。该融合基因含有编码泛素基因的DNA，其与编码生长因子受体或其片段的第二个DNA融合，在多种类型的癌症中表达。特别地，通过由突变的泛素基因和血管活性肠肽/垂体腺苷酸环化酶活化多肽受体-1（VPAC1）的修饰的超细胞结构域组成的重组融合基因来说明本发明。用疫苗免疫将通过有效的抗原加工和呈递来破坏肿瘤抗原的自身耐受性，导致肿瘤生长的延迟/消退。

6. 发明申请

WO2007057922A1 TARGETED FUSION PROTEINS FOR CANCER THERAPY 审中-公开
标题翻译：用于癌症治疗的目标融合蛋白
公开(公告)号：WO2007057922A1
公开(公告)日：2007-05-24
申请号：PCT/IN2006/000452
申请日：2006-11-16
申请人： DABUR PHARMA LIMITED , MAITHAL, Kapil , NACHIAPPAN, Dhatchana, Moorthy , MUKHERJEE, Rama
发明人： MAITHAL, Kapil , NACHIAPPAN, Dhatchana, Moorthy , MUKHERJEE, Rama
IPC分类号： C07K14/435 , A61K38/17
CPC分类号： A61K38/1709
摘要： The invention relates to fusion proteins useful as therapeutics against cancer. The fusion protein comprises of cell-targeting moiety and apoptosis-inducing moiety. Cell-targeting moiety and apoptosis-inducing moiety are linked by a flexible linker, which are specifically recognized by cancer specific protease and cleaved in situ to release the apoptotic domain. In particular, the invention is illustrated by a recombinant fusion protein between human Vasoactive Intestinal Peptide (VIP) and BH3 domain of Bcl2 family protein, linked by a linker that has site for cancer specific proteases. The fusion protein specifically targets VIP receptor over-expressing cancer cells and induces cell-specific apoptosis after cleavage at the linker site by cancer specific proteases. Such fusion proteins are useful for the delivery of therapeutic/apoptotic moiety (peptides) to specific cells with perturbed expression of, but not limited to neuropeptide receptors.
摘要翻译：本发明涉及可用作抗癌药物的融合蛋白。融合蛋白包含细胞靶向部分和凋亡诱导部分。细胞靶向部分和凋亡诱导部分通过柔性接头连接，柔性接头被癌特异性蛋白酶特异性识别并原位切割以释放凋亡结构域。特别地，本发明由人血管活性肽（VIP）和Bcl2家族蛋白的BH3结构域之间的重组融合蛋白说明，其通过具有癌症特异性蛋白酶位点的接头连接。融合蛋白特异性靶向VIP受体过表达癌细胞，并通过癌特异性蛋白酶在连接位点切割后诱导细胞特异性凋亡。这种融合蛋白可用于将治疗性/凋亡部分（肽）递送至具有神经肽受体的扰动表达但不限于特异性细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式